Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.
Zabaleta A, Puig N, Cedena MT, Oliver-Caldes A, Perez JJ, Moreno C, Tamariz-Amador LE, Rodriguez-Otero P, Prosper F, Gonzalez-Calle V, López-Corral L, Rey-Búa B, Puertas B, Mirás F, Sánchez-Pina JM, López-Muñoz N, Juan M, González-Navarro EA, Urbano Á, de Larrea CF, Blade J, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San Miguel JF, Paiva B. Zabaleta A, et al. Among authors: perez jj. Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27526. Online ahead of print. Am J Hematol. 2024. PMID: 39548827
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. Among authors: perez jj. J Clin Oncol. 2024 Oct 1:JCO2400635. doi: 10.1200/JCO.24.00635. Online ahead of print. J Clin Oncol. 2024. PMID: 39353166
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.
Gil-Prieto R, Pérez JJ, Drago G, Kieffer A, Roïz J, Kazmierska P, Sardesai A, de Boisvilliers S, López-Belmonte JL, Beuvelet M, Aldean JA. Gil-Prieto R, et al. Among authors: perez jj. BMC Infect Dis. 2024 Sep 6;24(1):924. doi: 10.1186/s12879-024-09642-0. BMC Infect Dis. 2024. PMID: 39242545 Free PMC article.
Protecting stable biological nomenclatural systems enables universal communication: A collective international appeal.
Jiménez-Mejías P, Manzano S, Gowda V, Krell FT, Lin MY, Martín-Bravo S, Martín-Torrijos L, Nieto Feliner G, Mosyakin SL, Naczi RFC, Acedo C, Álvarez I, Crisci JV, Luceño Garcés M, Manning J, Moreno Saiz JC, Muasya AM, Riina R, Meseguer AS, Sánchez-Mata D; 1543 additional coauthors. Jiménez-Mejías P, et al. Bioscience. 2024 Jun 19;74(7):467-472. doi: 10.1093/biosci/biae043. eCollection 2024 Jul. Bioscience. 2024. PMID: 39156614 Free PMC article.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV. Puig N, et al. Among authors: perez jj. Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285742. Online ahead of print. Haematologica. 2024. PMID: 38988266 Free article.
Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation.
Peralta-Moreno MN, Mena Y, Ortega-Alarcon D, Jimenez-Alesanco A, Vega S, Abian O, Velazquez-Campoy A, Thomson TM, Pinto M, Granadino-Roldán JM, Santos Tomas M, Perez JJ, Rubio-Martinez J. Peralta-Moreno MN, et al. Among authors: perez jj. Int J Mol Sci. 2024 Jun 1;25(11):6119. doi: 10.3390/ijms25116119. Int J Mol Sci. 2024. PMID: 38892306 Free PMC article.
294 results